Hajdari, Arsim and Velickova, Nevenka and Hajdari, Ardijana (2023) The Advantages of AntiVegf - Beovu Injections in the Treatment of Age-related Macular Degeneration - AMD. In: 12 th International Conference on Applied Medicine and Nursing IC-NUR 2023, Pristina, Kosovo.
Text
Final Agenda_2023.pdf Download (149kB) |
|
Text
Book-of-Abstracts-12th-International-28.11.2023.pdf Download (4MB) |
|
Text
Arsim hajdari_poster.pdf Download (351kB) |
Abstract
Introduction: Age-related macular degeneration (AMD) is the most common cause of blindness in developed countries. Neovascular (ie, wet) AMD is currently managed with intravitreal therapy. Traditional treatments (eg, bevacizumab, ranibizumab, aflibercept dhe Brolucizumab ) provide highly effective therapy but may also require frequent dosing.
Purpose: Continuous treatment and long-term chronic monitoring is a heavy economic and social burden on the patient, therefore the purpose is to evaluate what are the advantages of AntiVegf-Beovu injections.
Methodology: The research was done on 75 patients with AMD, average age 75 years, during 4 months at the Italian Eye Hospital in Pristina, Kosovo.
Conclusions: A large number of studies have shown high efficacy and safety for the advantages of AntiVegf-Beovu injections.After first 3 doses every 4 weeks and then 8-12 weeks ,thus reducing the frequency of receiving the antiVEGF injections used earlier ,also helping to reduce macular edema in patients with diabetes mellitus .Results with increased visual acuity and other evaluations with OCT and FA-OCT have shown high efficiency and safety for the advantages of ANTIVEGF-Brolucizumab injections .
Item Type: | Conference or Workshop Item (Poster) |
---|---|
Subjects: | Medical and Health Sciences > Basic medicine Medical and Health Sciences > Clinical medicine |
Divisions: | Faculty of Medical Science |
Depositing User: | Nevenka Velickova |
Date Deposited: | 17 May 2024 11:46 |
Last Modified: | 22 Aug 2024 10:38 |
URI: | https://eprints.ugd.edu.mk/id/eprint/34048 |
Actions (login required)
View Item |